Current Treatment Options in Neurology

, Volume 13, Issue 4, pp 427–435

Primary Brain Tumors in the Elderly Population

Neuro-oncology (Neoplasms)

Opinion statement

Elderly cancer patients are an important challenge in oncology, and clinical data from younger populations cannot be automatically considered applicable to unselected elderly patients with brain tumors, who tend to have more comorbidities and tolerate chemotherapy and radiotherapy less well than their younger counterparts. Most data available on elderly cancer patients are from retrospective studies that do not include age-specific enrollment criteria and are biased by intrinsic selection criteria governing enrollment. Most clinicians are unwilling to enroll elderly patients because of ageism and a fear of toxicity and poor outcome. Specifically designed trials based on genetic features and clinical factors are required to clearly establish the standard of care required for elderly patients with brain tumors, especially those with glioblastoma. Currently, surgery followed by radiotherapy is widely used for elderly glioblastoma patients, but temozolomide is the chemotherapeutic approach of choice for those with a relatively good clinical condition and prognosis. However, the schedule to follow and the best dosage have yet to be satisfactorily established.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. Epidemiology of brain tumors. Neurol Clin. 2007;25:867–90. vii.PubMedCrossRefGoogle Scholar
  2. 2.
    Central Brain Tumor Registry of the United States: 2009 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2005. Available at
  3. 3.
    Brandes AA, Compostella A, Blatt V, Tosoni A. Glioblastoma in the elderly: current and future trends. Crit Rev Oncol Hematol. 2006;60:256–66.PubMedCrossRefGoogle Scholar
  4. 4.
    Brandes AA, Monfardini S. The treatment of elderly patients with high-grade gliomas. Semin Oncol. 2003;30:58–62.PubMedCrossRefGoogle Scholar
  5. 5.
    Paszat L, Laperriere N, Groome P, Schulze K, Mackillop W, Holowaty E. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51:100–7.PubMedGoogle Scholar
  6. 6.
    Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64:628–34.PubMedCrossRefGoogle Scholar
  7. 7.
    Barker 2nd FG, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51:410–8.PubMedGoogle Scholar
  8. 8.
    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.PubMedCrossRefGoogle Scholar
  9. 9.•
    Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer. 2009;115:3512–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT. MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology. 2009;73:1509–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients–an analysis of the medical literature. J Clin Oncol. 2007;25:1832–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Solomon DH. Geriatric assessment: methods for clinical decision making. JAMA. 1988;259:2450–2.PubMedCrossRefGoogle Scholar
  13. 13.
    Kelly PJ, Hunt C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery. 1994;34:62–6. discussion 66–67.PubMedCrossRefGoogle Scholar
  14. 14.
    Whittle IR, Denholm SW, Gregor A. Management of patients aged over 60 years with supratentorial glioma: lessons from an audit. Surg Neurol. 1991;36:106–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Whittle IR, Basu N, Grant R, Walker M, Gregor A. Management of patients aged >60 years with malignant glioma: good clinical status and radiotherapy determine outcome. Br J Neurosurg. 2002;16:343–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people—a randomised study. Acta Neurochir (Wien). 2003;145:5–10.CrossRefGoogle Scholar
  17. 17.
    Ewelt C, Goeppert M, Rapp M, Steiger HJ, Stummer W, Sabel M: Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. J Neurooncol 2010 Oct 16 (Epub ahead of print).Google Scholar
  18. 18.
    Meckling S, Dold O, Forsyth PA, Brasher P, Hagen NA. Malignant supratentorial glioma in the elderly: is radiotherapy useful? Neurology. 1996;47:901–5.PubMedGoogle Scholar
  19. 19.
    Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356:1527–35.PubMedCrossRefGoogle Scholar
  20. 20.
    Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Scott J, Tsai YY, Chinnaiyan P, Yu HH: Effectiveness of radiotherapy for elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2010 Jul 31 (Epub ahead of print).Google Scholar
  22. 22.
    Grant R, Liang BC, Page MA, Crane DL, Greenberg HS, Junck L. Age influences chemotherapy response in astrocytomas. Neurology. 1995;45:929–33.PubMedGoogle Scholar
  23. 23.
    Pierga JY, Hoang-Xuan K, Feuvret L, Simon JM, Cornu P, Baillet F, et al. Treatment of malignant gliomas in the elderly. J Neurooncol. 1999;43:187–93.PubMedCrossRefGoogle Scholar
  24. 24.
    Gilbert M, O’Neill A, Grossman S, Grunnet M, Mehta M, Jubelirer S, et al. A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: an Eastern Cooperative Oncology Group study (E2393). J Neurooncol. 2000;47:145–52.PubMedCrossRefGoogle Scholar
  25. 25.
    Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17:2762–71.PubMedGoogle Scholar
  26. 26.
    Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer. 2003;97:2262–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Chinot OL, Barrie M, Frauger E, Dufour H, Figarella-Branger D, Palmari J, et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer. 2004;100:2208–14.PubMedCrossRefGoogle Scholar
  28. 28.
    Chamberlain MC, Chalmers L. A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. J Neurooncol. 2007;82:207–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Laigle-Donadey F, Figarella-Branger D, Chinot O, Taillandier L, Cartalat-Carel S, Honnorat J, Kaloshi G, Delattre JY, Sanson M: Up-front temozolomide in elderly patients with glioblastoma. J Neurooncol 99:89–94.Google Scholar
  30. 30.
    Brandes AA, Vastola F, Basso U, Berti F, Pinna G, Rotilio A, et al. A prospective study on glioblastoma in the elderly. Cancer. 2003;97:657–62.PubMedCrossRefGoogle Scholar
  31. 31.
    Combs SE, Wagner J, Bischof M, Welzel T, Wagner F, Debus J, et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys. 2008;70:987–92.PubMedCrossRefGoogle Scholar
  32. 32.
    Gerstein J, Franz K, Steinbach JP, Seifert V, Fraunholz I, Weiss C, et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol. 2010;97:382–6.PubMedCrossRefGoogle Scholar
  33. 33.••
    Malmstrom A, Gronberg BH, Stupp R, Marosi C, Frappaz D, Schultz HP, et al. Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ) [abstract]. J Clin Oncol. 2010;28(18 suppl):LBA2002.Google Scholar
  34. 34.••
    Wick W, Engel C, Combs SE, Nikkhah G, Steinbach J, Kortmann R, et al. NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem) [abstract]. J Clin Oncol. 2010;28(18 suppl):LBA2001.Google Scholar
  35. 35.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Medical Oncology, Bellaria-Maggiore HospitalAzienda USL of BolognaBolognaItaly

Personalised recommendations